심포니 및 심포니 아리아(골리무맙) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Simponi, Simponi Aria (Golimumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,661,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,629,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,596,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

심포니 및 심포니 아리아(골리무맙) 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 노인 인구 증가와 자가면역 질환의 유병률 상승, 염증성 장 질환의 유병률 증가, 관절염과 대장염 치료 옵션의 확대, 추가 적응증에 대한 임상 시험 진행, 비용 효율적인 생물학적 제제 솔루션에 대한 집중 등이 주요 요인으로 꼽힙니다. 예측 기간의 주요 동향으로는 자가 면역 치료에 바이오시밀러의 채택 증가, 피하 투여 방법의 성장, 병용 요법의 사용 증가, 생물학적 제제 시장 점유율의 확대, 환자 관리에 AI 및 기계 학습의 통합 등이 있습니다.

자가 면역 질환의 유병률 증가는 심포니 및 심포니 아리아(골리무맙) 시장의 성장을 촉진할 것으로 예상됩니다. 자가 면역 질환은 신체의 면역 체계가 자신의 건강한 세포와 조직을 이물질로 인식하여 공격할 때 발생합니다. 류마티스 관절염의 발병률은 유전적, 환경적, 생활 습관적 요인의 조합으로 인해 증가하고 있습니다. 심포니 및 심포니 아리아(골리무맙)는 류마티스 관절염, 궤양성 대장염, 강직성 척추염, 건선 관절염과 같은 자가 면역 질환을 표적으로 하는 효과적인 생물학적 치료제입니다. 예를 들어, 2022년 5월 영국 기반 자선 단체인 통증 완화 재단은 관절염과 근골격계 질환이 영국에서 1,700만 명 이상에게 영향을 미쳐 매년 3,000만 일의 근로일 손실을 초래한다고 보고했습니다. 또한 만성 통증은 75세 이상 인구의 최대 62%에게 영향을 미치며, 고령화 인구로 인한 통증 부담의 증가를 강조합니다. 이에 따라 자가면역 질환의 유병률 증가가 심포니 및 심포니 아리아(골리무맙) 시장 성장에 기여하고 있습니다.

시장의 주요 동향은 EU 및 영국에서 자가 면역 질환에 대한 생물학적 제제 치료에 대한 환자의 접근성을 개선하기 위해 심포니 (골리무맙)의 비용 효율적인 대체품을 개발하는 것입니다. 골리무맙 바이오시밀러는 오리지널 심포니와 매우 유사한 생물학적 의약품으로, 자가 면역 질환을 치료하는 데 사용되며, 잠재적으로 더 낮은 비용으로 유사한 안전성과 효능을 제공합니다. 예를 들어, 2024년 5월 중국 기반 바이오제약 기업 Bio-Thera Solutions와 독일 제약사 STADA Arzneimittel AG는 시몬피의 바이오시밀러인 BAT2506의 독점 상업화 및 라이선스 계약을 체결했습니다. Bio-Thera는 BAT2506의 개발, 제조, 공급을 담당하며, STADA는 EU, 영국, 스위스 및 특정 다른 국가에서 해당 제품을 독점적으로 상업화할 권리를 보유합니다. 이 협력은 류마티스 관절염과 건선성 관절염과 같은 자가면역 질환 치료를 위해 심포니의 저렴하고 고품질 대안을 제공하는 것을 목표로 합니다. 이 계약에는 잠재적 마일스톤 지급 조건이 포함되어 면역학 분야에서 생물학적 치료제의 접근성 확대 중요성을 강조하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 심포니 및 심포니 아리아(골리무맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 : 성장률 분석
• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 심포니 및 심포니 아리아(골리무맙) : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 유형 I
• 유형 II
• 유형 III
• 유형 IV
• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 피하 주사
• 정맥내 주입
• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 : 임상 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 류마티스 관절염
• 건선성 관절염
• 강직성 척추염
• 궤양성 대장염
• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 심포니 및 심포니 아리아(골리무맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 심포니 및 심포니 아리아(골리무맙) 시장 : 경쟁 구도
• 심포니 및 심포니 아리아(골리무맙) 시장 : 기업 프로파일
  • Merck & Co. Inc.
  • Johnson & Johnson
  • Alvotech

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 심포니 및 심포니 아리아(골리무맙) 시장(2029년) : 새로운 기회를 제공하는 국가
• 심포니 및 심포니 아리아(골리무맙) 시장(2029년) : 새로운 기회를 제공하는 부문
• 심포니 및 심포니 아리아(골리무맙) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

Simponi and Simponi Aria (Golimumab) are biologic medications that target tumor necrosis factor-alpha (TNF-alpha) to help reduce inflammation in autoimmune conditions. They are prescribed to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Primary types of simponi and simponi aria (Golimumab) include type I, type II, type III, and type IV. These medications are administered via key routes such as subcutaneous injection and intravenous infusion. The main clinical indications for their use are rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. They are primarily utilized in hospitals and clinics.

The simponi, simponi aria (golimumab) market research report is one of a series of new reports from The Business Research Company that provides simponi, simponi aria (golimumab) market statistics, including simponi, simponi aria (golimumab) industry global market size, regional shares, competitors with a simponi, simponi aria (golimumab) market share, detailed simponi, simponi aria (golimumab) market segments, market trends and opportunities, and any further data you may need to thrive in the simponi, simponi aria (golimumab) industry. This simponi, simponi aria (golimumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The simponi, simponi aria (golimumab) market size is expected to see strong growth in the next few years. It will grow to $32,213 million in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to rising geriatric population with autoimmune conditions, increasing prevalence of inflammatory bowel diseases, expanding treatment options for arthritis and colitis, ongoing clinical trials for additional indications, and focus on cost-effective biologic solutions. Major trends in the forecast period include rising adoption of biosimilars in autoimmune treatment, growth of subcutaneous delivery methods, increasing use of combination therapies, expansion in biologics market share, and integration of AI and machine learning in patient management.

The rising prevalence of autoimmune diseases is expected to drive the growth of the simponi, simponi aria (golimumab) market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, treating them as foreign invaders. The incidence of rheumatoid arthritis is increasing due to a combination of genetic, environmental, and lifestyle factors. Simponi and Simponi Aria (golimumab) are effective biologic treatments that target autoimmune diseases like rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. For example, in May 2022, the Pain Relief Foundation, a UK-based charity, reported that arthritis and musculoskeletal conditions affect over 17 million people in the UK, leading to 30 million lost working days each year. Additionally, chronic pain impacts up to 62% of those over 75, highlighting the growing burden of pain due to an aging population. Consequently, the increasing prevalence of autoimmune diseases is contributing to the growth of the simponi, simponi aria (golimumab) market.

A key trend in the simponi, simponi aria (golimumab) market is the development of cost-effective alternatives to Simponi (golimumab) to improve patient access to biologic treatments for autoimmune diseases in the EU and UK. Golimumab biosimilars are biologic drugs that closely resemble the original Simponi and are used to treat autoimmune conditions, offering comparable safety and efficacy at potentially lower costs. For example, in May 2024, Bio-Thera Solutions, a China-based biopharmaceutical company, and STADA Arzneimittel AG, a German pharmaceutical company, entered into an exclusive commercialization and licensing agreement for BAT2506, a biosimilar to Simponi. Bio-Thera is responsible for the development, manufacturing, and supply of BAT2506, while STADA has exclusive rights to commercialize it in the EU, UK, Switzerland, and select other countries. This collaboration aims to provide an affordable, high-quality alternative to Simponi for treating autoimmune diseases like rheumatoid arthritis and psoriatic arthritis. The agreement also includes potential milestone payments, emphasizing the importance of expanding access to biologic treatments in immunology.

In May 2023, Alvotech, an Icelandic biotechnology company, announced a partnership with Advanz Pharma to improve patient access to affordable biologics. This partnership leverages Alvotech's expertise in the development and commercial supply alongside Advanz Pharma's capabilities in registration and commercialization within the European market. Advanz Pharma, a UK-based biotechnology company, is involved in the development of biologics such as simponi.

Major players operating in the simponi, simponi aria (golimumab) market are Merck & Co. Inc., Johnson & Johnson, and Alvotech.

North America was the largest region in the simponi, simponi aria (golimumab) market in 2024. The regions covered in simponi and simponi aria (golimumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the simponi and simponi aria (golimumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The simponi and simponi aria (golimumab) market consists of sales of syringes, autoinjectors, and intravenous infusion formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Simponi, Simponi Aria (Golimumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on simponi, simponi aria (golimumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for simponi, simponi aria (golimumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The simponi, simponi aria (golimumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type I; Type II; Type III; Type IV
• 2) By Administration Route: Subcutaneous Injection; Intravenous Infusion
• 3) By Clinical Indications: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Ulcerative Colitis
• 4) By Application: Hospital; Clinic
• Companies Mentioned: Merck & Co. Inc.; Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Simponi, Simponi Aria (Golimumab) Market Characteristics

3. Simponi, Simponi Aria (Golimumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Simponi, Simponi Aria (Golimumab) Market Trends And Strategies

5. Simponi, Simponi Aria (Golimumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Simponi, Simponi Aria (Golimumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Simponi, Simponi Aria (Golimumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Simponi, Simponi Aria (Golimumab) Market Growth Rate Analysis
• 6.4. Global Simponi, Simponi Aria (Golimumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Simponi, Simponi Aria (Golimumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Simponi, Simponi Aria (Golimumab) Total Addressable Market (TAM)

7. Global Simponi, Simponi Aria (Golimumab) Market Pricing Analysis & Forecasts

8. Simponi, Simponi Aria (Golimumab) Market Segmentation

• 8.1. Global Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type I
• Type II
• Type III
• Type IV
• 8.2. Global Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous Injection
• Intravenous Infusion
• 8.3. Global Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Ulcerative Colitis
• 8.4. Global Simponi, Simponi Aria (Golimumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic

9. Global Simponi, Simponi Aria (Golimumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Simponi, Simponi Aria (Golimumab) Market Regional And Country Analysis

• 10.1. Global Simponi, Simponi Aria (Golimumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Simponi, Simponi Aria (Golimumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Simponi, Simponi Aria (Golimumab) Market

• 11.1. Asia-Pacific Simponi, Simponi Aria (Golimumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Simponi, Simponi Aria (Golimumab) Market

• 12.1. China Simponi, Simponi Aria (Golimumab) Market Overview
• 12.2. China Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Simponi, Simponi Aria (Golimumab) Market

• 13.1. India Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Simponi, Simponi Aria (Golimumab) Market

• 14.1. Japan Simponi, Simponi Aria (Golimumab) Market Overview
• 14.2. Japan Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Simponi, Simponi Aria (Golimumab) Market

• 15.1. Australia Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Simponi, Simponi Aria (Golimumab) Market

• 16.1. South Korea Simponi, Simponi Aria (Golimumab) Market Overview
• 16.2. South Korea Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Simponi, Simponi Aria (Golimumab) Market

• 17.1. Western Europe Simponi, Simponi Aria (Golimumab) Market Overview
• 17.2. Western Europe Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Simponi, Simponi Aria (Golimumab) Market

• 18.1. UK Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Simponi, Simponi Aria (Golimumab) Market

• 19.1. Germany Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Simponi, Simponi Aria (Golimumab) Market

• 20.1. France Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Simponi, Simponi Aria (Golimumab) Market

• 21.1. Eastern Europe Simponi, Simponi Aria (Golimumab) Market Overview
• 21.2. Eastern Europe Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Simponi, Simponi Aria (Golimumab) Market

• 22.1. North America Simponi, Simponi Aria (Golimumab) Market Overview
• 22.2. North America Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Simponi, Simponi Aria (Golimumab) Market

• 23.1. USA Simponi, Simponi Aria (Golimumab) Market Overview
• 23.2. USA Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Simponi, Simponi Aria (Golimumab) Market

• 24.1. Canada Simponi, Simponi Aria (Golimumab) Market Overview
• 24.2. Canada Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Simponi, Simponi Aria (Golimumab) Market

• 25.1. South America Simponi, Simponi Aria (Golimumab) Market Overview
• 25.2. South America Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Simponi, Simponi Aria (Golimumab) Market

• 26.1. Middle East Simponi, Simponi Aria (Golimumab) Market Overview
• 26.2. Middle East Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Simponi, Simponi Aria (Golimumab) Market

• 27.1. Africa Simponi, Simponi Aria (Golimumab) Market Overview
• 27.2. Africa Simponi, Simponi Aria (Golimumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Simponi, Simponi Aria (Golimumab) Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Simponi, Simponi Aria (Golimumab) Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Simponi, Simponi Aria (Golimumab) Market Competitive Landscape And Company Profiles

• 28.1. Simponi, Simponi Aria (Golimumab) Market Competitive Landscape
• 28.2. Simponi, Simponi Aria (Golimumab) Market Company Profiles
  • 28.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. Alvotech Overview, Products and Services, Strategy and Financial Analysis

29. Global Simponi, Simponi Aria (Golimumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Simponi, Simponi Aria (Golimumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Simponi, Simponi Aria (Golimumab) Market

32. Recent Developments In The Simponi, Simponi Aria (Golimumab) Market

33. Simponi, Simponi Aria (Golimumab) Market High Potential Countries, Segments and Strategies

• 33.1 Simponi, Simponi Aria (Golimumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Simponi, Simponi Aria (Golimumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Simponi, Simponi Aria (Golimumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer

관련자료